Open access

Visiting scientists to the Open Lab often cite access to world-class facilities and the opportunity to work with scientists who work in the drug discovery field as the key benefits of the Open Lab’s unique approach.

From its home at the Tres Cantos Medicines Development Campus, the Open Lab gives visiting scientists access to GlaxoSmithKline drug discovery, pre-clinical expertise, capabilities and the benefits of working as part of a project team.

This bold and flexible approach has positioned the Open Lab as a dynamic research hub for diseases of the developing world, helping to stimulate innovative research that could ultimately result in the discovery and development of new medicines.

The Open Lab provides access to:

  • Biosafety Level 3 in vitro and in vivo laboratories which are used as research or production facilities where work is conducted with pathogens that may cause serious or potentially lethal diseases after inhalation, including TB. The laboratories have special engineering and design features to ensure full decontamination. Laboratory personnel have specific training in handling pathogenic and potentially lethal agents.
  • The Drug Performance Units (DPUs) which are focused on malaria, TB and Kinetoplastids are independent but coordinated units equipped with all the human and technical resources needed to effectively address the challenges of each disease.
  • GSK’s ultra high-throughput world-class screening (uHTS) facility specialises in identifying chemical starting points for drug discovery activities.
    • The uHTS offers Open Lab scientists new opportunities to apply cutting-edge science and technology in lead discovery and compound profiling including assay development, HTS, computational chemistry, data analysis, IT and cell culture.
    • These screening facilities are of huge importance in the initial stages of drug discovery. Automated and robotic systems have been installed for chemical compound management, to perform high throughput screening tests and also to culture cells. These facilities are one of the most advanced in the pharmaceutical industry, with a capacity to perform hundreds of thousands of biochemical and cellular experiments every day.
    • The facilities offer a large degree of flexibility to accommodate a variety of technologies and assay types. Different screening strategies approaches are integrated, such as HTS of focused sets, fragment-based lead discovery, knowledge-based screening and comprehensive compound profiling of biological liabilities.
  • GSK’s complete compound screening library currently stands at more than two million compounds. The collection of chemical products is located in an automated compound store with a capacity for about 2.2 million individual samples.

The combination of these facilities and expertise enables this DDW centre to take care of all scientific phases of drug discovery and development from screening campaigns to clinical Proof of Concept studies. (Phase IIb)